Share This Page
Bulk Pharmaceutical API Sources for FLUOTREX
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for FLUOTREX
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| TCI (Tokyo Chemical Industry) | ⤷ Start Trial | F0657 | ⤷ Start Trial |
| Molport | ⤷ Start Trial | MolPort-002-528-328 | ⤷ Start Trial |
| Hangzhou APIChem Technology | ⤷ Start Trial | AC-429 | ⤷ Start Trial |
| AKos Consulting & Solutions | ⤷ Start Trial | AKOS015963144 | ⤷ Start Trial |
| Finetech Industry Limited | ⤷ Start Trial | FT-0631295 | ⤷ Start Trial |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
Bulk Active Pharmaceutical Ingredient (API) Sources for FLUOTREX
FLUOTREX (generic: fluoxetine) is a selective serotonin reuptake inhibitor (SSRI) indicated for depression, obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder. Supply chain reliability depends on the availability of high-quality API manufacturers.
Primary API Manufacturers for Fluoxetine
Major suppliers of fluoxetine API are concentrated geographically in certain regions with established pharmaceutical manufacturing infrastructure. Notable sources include:
| Manufacturer | Location | Production Capabilities | Regulatory Status | Notes |
|---|---|---|---|---|
| Ranbaxy Laboratories Ltd. | India | Large-scale production | Approved by US FDA, EMA | Historically primary supplier; manufacturing shifted following acquisition by Sun Pharmaceutical Industries |
| Teva Pharmaceutical Industries Ltd. | Israel | High-volume API manufacturing | FDA approved | Supplies globally, state-of-the-art GMP facilities |
| Hubei Wuchang Pharmaceutical Factory | China | API production | Chinese GMP; limited international approval | Often used for regional markets |
| Zhejiang Hangzhou Pharmaceutical Co. | China | API synthesis | Chinese GMP approval | Increasing presence in global supply chains |
| Shanghai Fosun Pharmaceutical Co. | China | API manufacturing | Chinese regulatory approval | Growing capabilities in API quality control |
Regional Analysis of API Supply
North America
The US and Canada primarily import fluoxetine APIs from approved manufacturers such as Teva and Ranbaxy, which meet stringent US FDA standards.
Asia-Pacific
China and India dominate API production for fluoxetine. Chinese manufacturers mainly focus on regional demand with some exports, while Indian firms, particularly Sun Pharma and Dr. Reddy's Laboratories, supply globally with rigorous GMP compliance.
Europe
European suppliers rely on Teva and local manufacturers aligned with EMA standards. Regulatory oversight is more rigorous, restricting API sources to approved entities.
Regulatory Considerations
Manufacturers must comply with Good Manufacturing Practices (GMP). API suppliers often hold approvals such as FDA 21 CFR Part 211, EMA GMP certificates, or Chinese GMP licenses.
Supply Chain Risks and Constraints
- Regulatory shifts: Stricter international import regulations may impact Chinese and Indian API exports.
- Capacity limitations: Sudden surges in demand can strain existing manufacturers.
- Quality variations: Differences exist in API purity and consistency between sources; comprehensive audits are necessary.
- Geopolitical factors: Trade tensions influence supplier accessibility and cost.
Alternatives and Emerging Sources
- Vertical integration: Major pharmaceutical firms often develop in-house API synthesis capabilities.
- Contract manufacturing organizations (CMOs): Contracted providers expand capacity but require thorough qualification.
- Reformulation efforts: Some companies explore alternative synthetic routes to reduce dependence on traditional sources.
Summary of Key API Suppliers
| Supplier | Region | Certifications | Market Focus | Notes |
|---|---|---|---|---|
| Teva | Israel | FDA, EMA | Global | Large-scale, quality assurance |
| Sun Pharma | India | FDA, CE | Global | Increased capacity post-acquisition |
| Dr. Reddy's | India | GMP approved | Global | Focus on cost-effective supplies |
| Hubei Wuchang | China | Chinese GMP | Regional | Lower cost, variable quality |
| Zhejiang Hangzhou | China | Chinese GMP | Regional/global | Growing exporter |
Key Takeaways
- Leading global APIs for fluoxetine originate from India (Sun Pharma, Dr. Reddy’s), Israel (Teva), and China (Hubei, Zhejiang).
- Regulatory approval and GMP certification are critical for supply reliability.
- Chinese API manufacturers primarily serve regional markets unless they obtain international certifications.
- Supply chain resilience depends on diversified supplier bases and ongoing quality validation.
FAQs
1. Which are the most reliable sources of fluoxetine API?
Teva and Sun Pharma supply high-quality APIs globally, with regulatory certifications ensuring consistent quality.
2. What regions dominate fluoxetine API manufacturing?
India and China lead, with established facilities adhering to international standards.
3. How do regulatory standards impact API sourcing?
Manufacturers must hold GMP certifications (FDA, EMA, Chinese GMP) to access global markets and ensure API safety.
4. Are there alternative synthetic routes for fluoxetine API?
Research efforts exist but typically require substantial validation; most manufacturers rely on established syntheses.
5. What supply risks should companies monitor?
Regulatory changes, capacity constraints, geopolitical factors, and quality issues can disrupt APIs’ availability.
References
[1] U.S. Food and Drug Administration. (2022). Drug Master File. https://www.fda.gov/drugs/drug-master-files
[2] European Medicines Agency. (2021). Certificate of Suitability. https://www.ema.europa.eu/en/human-regulatory/research-development/compliance/chemical-pharmaceutical-quality/validation
[3] MarketWatch. (2023). Global API Market Overview. https://www.marketwatch.com/market-data/api-market
More… ↓
